GoodRx Holdings, Inc. $GDRX Stock Holdings Reduced by Rip Road Capital Partners LP

Key Points

• Rip Road Capital Partners LP reduced its stake in GoodRx Holdings by 20.2% in Q1, now holding 1,923,068 shares, which constitutes 9.3% of its overall investment portfolio.
• GoodRx reported Q2 earnings per share of $0.09, missing estimates by $0.01, and had a revenue of $203.07 million, slightly below the expected $205.72 million.
• Analysts have downgraded GoodRx's stock price target, with UBS cutting it to $5.25 from $6.00, indicating a prevailing "neutral" rating among investment analysts.

Rip Road Capital Partners LP reduced its holdings in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 20.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,923,068 shares of the company's stock after selling 485,509 shares during the period. GoodRx comprises approximately 9.3% of Rip Road Capital Partners LP's portfolio, making the stock its 3rd biggest holding. Rip Road Capital Partners LP owned about 0.50% of GoodRx worth $8,481,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. 8 Knots Management LLC bought a new stake in GoodRx in the first quarter valued at $8,106,000. EVR Research LP increased its position in shares of GoodRx by 243.3% during the 1st quarter. EVR Research LP now owns 1,300,000 shares of the company's stock valued at $5,733,000 after purchasing an additional 921,337 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in GoodRx by 303.3% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,061,461 shares of the company's stock worth $4,936,000 after acquiring an additional 798,261 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in GoodRx by 22.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company's stock worth $9,264,000 after acquiring an additional 369,553 shares in the last quarter. Finally, Two Sigma Investments LP boosted its stake in GoodRx by 98.1% in the 4th quarter. Two Sigma Investments LP now owns 722,374 shares of the company's stock worth $3,359,000 after purchasing an additional 357,674 shares during the period. 63.77% of the stock is owned by hedge funds and other institutional investors.

GoodRx Stock Up 0.4%

Shares of NASDAQ GDRX traded up $0.02 during midday trading on Tuesday, hitting $4.14. 343,658 shares of the company's stock were exchanged, compared to its average volume of 2,010,145. The firm's fifty day simple moving average is $4.49 and its 200-day simple moving average is $4.45. The company has a market cap of $1.44 billion, a PE ratio of 41.37, a P/E/G ratio of 1.74 and a beta of 1.23. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.21 and a quick ratio of 4.21. GoodRx Holdings, Inc. has a twelve month low of $3.31 and a twelve month high of $7.90.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The company had revenue of $203.07 million during the quarter, compared to analysts' expectations of $205.72 million. During the same quarter last year, the business posted $0.08 earnings per share. The company's revenue for the quarter was up 1.2% compared to the same quarter last year. Research analysts predict that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. UBS Group lowered their price target on GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $6.00 price objective on shares of GoodRx in a research report on Monday, August 11th. Finally, Raymond James Financial downgraded GoodRx from a "strong-buy" rating to an "outperform" rating in a report on Friday, August 8th. Five analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, GoodRx currently has a consensus rating of "Hold" and an average price target of $5.80.

Insider Activity at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 16,016 shares of the firm's stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $4.05, for a total transaction of $64,864.80. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.17% of the stock is currently owned by company insiders.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.